Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
hccf BUY
To All---Stockwillrock---phone call to Darci
I asked her about company in India, new possible products, shipment coming in from India in June, test results..marketing campaign....etccc
And I will now give answers--drumroll first---Ok I feel this is all very positive news and feel that they are trying to get everything in place now before they really begin the campaign---The company in India is called Balance Nutritional Systems--they will rpovide the first shipment this June----as far as 100% June 1st---we shall see ---she says that June is the month and the first half is when everything is expected but did not give or was reluctant to say 100% 1st week of June (I do not blame her--it is coming)---ALso this to me is better news---they are toward the end phase of negotiations with a very well respected manufacturing plant that is a top-notch manufacturer and will do all the testing, have climate controlled plant, and will be able to ensure safer product (testing)here in the USA, I assume a lot cheaper and more efficient---I personally expect a PR concerning this in the next couple of weeks....Now ---I also expect a PR end of this week of early next week on testing results of the patients (testimonials coming soon but not with their names because of an agreement)---I think and expressedthe fact we need an easy to read format and it is important that there is no confusion with the results---I feel that these results will get us to the next level along with the Manufacturing of the product PR hopefully to follow and some new products in the near future--possibly two of them. The Advertising ---Darci tells me that Media Imp is diligently working on a strategy this month concerning the different ways they willl market and I know Radley is going to Chicago tomorrow (this week to meet with them)---They will probably start the campaign end of June early July after the strategy is aggreed upon----I think is all ---She is very positive about this coming month or two---and I am looking forward to some great PR's and results especially with test results, manufacturing plant negotiations, and new products in the pipeline---
I am out--Ryan
Rest gives friend takes hee HCCF
hccf buy
Albert
I hope all is well.
I saw the post you did on Ihub and RB regarding an email from Darci. On Raging Bull it was post 10746.
Do me a big favor and forward he email to me?
Thank you.
BTW, have you seen my new company yet?
Herbert L. Becker
Direct phone and fax 206-350-5392
-----Original Message-----
The magnitude of this has the possibility of HCCF shares skyrocketing.
Diabetes is often accompanied by heart enlargement, heart dysfunction and coronary heart disease.
Heart disease is the leading cause of death in people with diabetes (SEE THE CONNECTION).
I think Hee Corp. has pulled off a hell of a one-two punch in its battle against Type II Diabetes.
As of April 28, the World Health Organization estimates 180 million people have type 2 diabetes
Albert buy.....
ASNI 95% HY BUYYYYYYYY
Friend, This share goes to 014 soon ASNI
tlantic Syndication Network, Inc. (OTCBB: ASNI) Announces Network Television Shows on Major Cable Networks
ASNI has negotiated the purchase of weekly block time to launch and distribute television shows and infomercials on a number of cable channels such as Delphi, Comcast, AT&T, Time Warner and Cox. Phase Two will add in excess of 100 cities and approximately 20 million homes.
(PRWEB) January 28, 2005 -- ASNI has negotiated the purchase of weekly block time to launch and distribute existing television shows and infomercials and for the sale of additional media time to other producers and production companies. During Phase One of ASNI's upcoming network (working title ASNI.TV) the company is scheduled to be on the air 4 hours daily, 5 nights per week from 10PM to 2AM in Southern California. The initial launch (date to be announced)is scheduled on a number of cable channels such as Delphi, Comcast, AT&T, Time Warner and Cox. Existing studio and independent producer commitments indicate the network will fulfill these hours and expand its commitment nationally into Phase Two which will add in excess of 100 cities and approximately 20 million homes.
ASNI's business development phaseis over and the company believes established relationships with entertainment, media distribution and internet development companies will enhance the launch of its network and shows. Projected revenues for fiscal year 2005 should range between 3 to 5 million dollars (US)or 10 to 17 cents per share earning and income in fiscal 2006 will increase exponentially when ASNI's scheduled projects and Phase Two of ASNI.TV network are implemented.
Television as the dominant medium in America has taken quantitative leaps in recent years and viewers are no longer limited to a dozen or so local broadcasting stations. Even the vastly improved 64 channel cable TV systems have given way to the 500 channel digital services that have spread across the country and the DBS or Direct Broadcast Satellite services preferred by millions of viewers. Many channels are now becomming "interactive" and this is projected to literally turn TV sets into two-way communication devices.
This has made Programs-On-Demand aka "POD's" a reality.ASNI is agressively developing projects for this medium.The advent of video streaming the programs over the internet has laid the foundation for convergence or the combining of traditional television with internet services and other activities.
The rapidly expanding channels have created a varacious appetite for content. The term broadcasting has given way to "narrowcasting". No longer is a TV network all things to all people. Today, networks specialize; Golf Channel for golfers, Lifetime Channel for women, ESPN for sports fans, etc. Thus the growing demand for niche programming is creating new and lucrative opportunities for companies such as ASNI.
ASNI's mission is to be a leader in the development, production and distribution of innovative programming and infomercials of unique capacity and be a leader in interactive television providing clientele state-of-the-art video streaming on the web. Networks are categorically targeting today's audience with niche marketing, aka "narrowcasting". ASNI's focus is the promotion of special interest programs which are highly marketable and profitable with opportunity for significant long-term residual income.
Safe Harbor:Note:Included in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as ammended, and Section 21E of the Securities Exchange Act of 1934, as ammended, and is subject to safe harbor created by those sections. Although the company believes such expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove correct. The company's actual results could differ materially from those anticipated in the forward-looking statements as a result of certain internal and external factors.
www.asni.tv
# # #
Related News Releases ( What's this? )
ASNI BUY>>>> 0.036/0.07
Friend, The trade is today Otterman dead, within two weeks more trade 0.04 after the test of hpb84 BUY>>>>>>>>>>>>>>
Albert
HCCF/HEE 0.02
Vriends HCCF BUY>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Hee.Corp HCCF BUY>>>>>>>>>>>>>>>>>>>>>>> 002
Chelation Therapy
AHA Recommendation
The American Heart Association has reviewed the available literature on using chelation (ke-LA'shun) (E.D.T.A., ethylenediamine tetraacetic acid) to treat arteriosclerotic (ar-te"re-o-skleh-ROT'ik) heart disease. We found no scientific evidence to demonstrate any benefit from this form of therapy.
Chelation therapy is a recognized treatment for heavy metal (such as lead) poisoning. EDTA, injected into the blood, will bind the metals and allow them to be removed from the body in the urine. Chelation therapy is not approved by the FDA to treat coronary artery disease, but some physicians and alternative medicine practitioners use it for this purpose.
Up to now, there have been no adequate, controlled, published scientific studies using currently approved scientific methodology to support this therapy for cardiovascular disease. The United States Food and Drug Administration (FDA), the National Institutes of Health (NIH) and the American College of Cardiology all agree with the American Heart Association on this point.
In August 2002, the National Center for Complementary and Alternative Medicine (NCCAM) and the National Heart, Lung, and Blood Institute (NHLBI), which are both components of the National Institutes of Health (NIH), announced that they have launched the Trial to Assess Chelation Therapy (TACT). This will be the first large-scale, multicenter study to find out if EDTA chelation therapy is safe and effective for people with coronary heart disease. This placebo-controlled, double-blind study will involve 2,372 participants age 50 years and older who’ve had a heart attack. They will be representative of the U.S. population. TACT will be more than 20 times larger than any prior study of chelation therapy — large enough to show if chelation therapy has mild or moderate benefits.
This study is being done because there is a public health need to conduct a large, well-designed clinical trial to find out if chelation therapy is safe and effective for treating people with coronary heart disease. If people use chelation therapy and it doesn’t work, they may be deprived of the well-established benefits from the many other valuable methods of treating these diseases, such as lifestyle modifications, medications and surgical procedures.
The trial will take place at about 100 research sites across the United States and will test EDTA chelation therapy by using the most widely practiced means of administering it. Participants will begin being recruited in March 2003; patients will receive 30 weekly intravenous treatments, then 10 more treatments given bimonthly, over a 28-month period. They will also receive high doses of vitamins, which are also often given with chelation therapy. (The effect of such vitamin doses will also be examined in the trial.) Once recruitment begins, the study will take about five years to complete. To learn more about this study, visit nccam...nih...gov and ClinicalTrials...gov.
For more information about chelation therapy, see the American Heart Association online pamphlet, Questions and Answers About Chelation Therapy.
BUY>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
Friends, Realm becomes with hee this is possible within 2 years rate 13 dolar
Hee Corp BY????????????? 0.02
This is forget a share never HCCF
ere it is
HEE Corporation Announces Heart-Healthy Metobolic Product
Thursday May 19, 9:43 am ET
HPB-Artery Klenz to serve as an oral supplement for heart disease.
HUTCHINSON, Kan., May 19 /PRNewswire-FirstCall/ -- HEE Corporation Inc. (OTC Bulletin Board: HCCF - News) announced today the acquisition of a natural oral chelate, or detoxifying agent, designed to inhibit and repair the damaging effects of heart disease. Tentatively named "HPB-Artery Klenz," the metabolic product is intended to offer a preventative solution to cardiovascular dysfunction and provide a potential alternative to coronary bypass surgery.
Approximately 40 million Americans suffer from heart disease and nearly 300,000 undergo coronary artery bypass surgery every year. According to HEE Corporation President Radley Brooks, "The addition of Artery Klenz to our product mix will allow the consumer a safe and inexpensive formula for dealing with potential heart disease both before and after it becomes problematic and will help minimize the need for invasive surgical procedures."
Manufactured in the United States, HPB-Artery Klenz, "not only has the ability to remove calcium and plaque deposits from narrowed blood vessels, but will also improve metabolic and circulatory functions by removing various toxic metals such as iron, lead, mercury and cadmium," said Brooks.
Chelation is a metabolic medical treatment that has the capability of reducing high blood pressure and cholesterol, at the same time helping to eliminate arterial plaque, not only in the heart, but throughout the body. Working in concert with traditional medical techniques and remedies, HPB- Artery Klenz shows promise in making significant strides in the prevention and repair of the damaging effects of heart disease.
In April, HEE Corporation announced the launch of its web-based product sales and information site, . The exclusive international distributor of HPB-84, a nutriceutical developed in India, HEE Corporation has spent the past year testing and developing the promising nutriceutical for Type II diabetes. Similarly, HEE Corporation will conduct a thorough testing of HPB-Artery Klenz as the next addition to its product mix of natural products developed for metabolic syndrome. At the conclusion of such scientifically stringent testing, HPB-Artery Klenz will join the HEE Corporation family of naturopathic metabolic remedies for the treatment of catastrophic diseases.
About HEE
HEE's headquarters is based in Hutchinson, Kansas.
Forward-Looking Statements:
Advertisements
HPB-Artery Klenz to serve as an oral supplement for heart disease. HUTCHINSON, Kan. - PRNewswire-FirstCall - May 19
HUTCHINSON, Kan., May 19 /PRNewswire-FirstCall/ -- HEE Corporation Inc. (OTC:HCCF) (BULLETIN BOARD: HCCF) announced today the acquisition of a natural oral chelate, or detoxifying agent, designed to inhibit and repair the damaging effects of heart disease. Tentatively named "HPB-Artery Klenz," the metabolic product is intended to offer a preventative solution to cardiovascular dysfunction and provide a potential alternative to coronary bypass surgery.
Approximately 40 million Americans suffer from heart disease and nearly 300,000 undergo coronary artery bypass surgery every year. According to HEE Corporation President Radley Brooks, "The addition of Artery Klenz to our product mix will allow the consumer a safe and inexpensive formula for dealing with potential heart disease both before and after it becomes problematic and will help minimize the need for invasive surgical procedures."
Manufactured in the United States, HPB-Artery Klenz, "not only has the ability to remove calcium and plaque deposits from narrowed blood vessels, but will also improve metabolic and circulatory functions by removing various toxic metals such as iron, lead, mercury and cadmium," said Brooks.
Chelation is a metabolic medical treatment that has the capability of reducing high blood pressure and cholesterol, at the same time helping to eliminate arterial plaque, not only in the heart, but throughout the body. Working in concert with traditional medical techniques and remedies, HPB- Artery Klenz shows promise in making significant strides in the prevention and repair of the damaging effects of heart disease.
In April, HEE Corporation announced the launch of its web-based product sales and information site, http://www.hpb84.net/ . The exclusive international distributor of HPB-84, a nutriceutical developed in India, HEE Corporation has spent the past year testing and developing the promising nutriceutical for Type II diabetes. Similarly, HEE Corporation will conduct a thorough testing of HPB-Artery Klenz as the next addition to its product mix of natural products developed for metabolic syndrome. At the conclusion of such scientifically stringent testing, HPB-Artery Klenz will join the HEE Corporation family of naturopathic metabolic remedies for the treatment of catastrophic diseases.
About HEE
HEE's headquarters is based in Hutchinson, Kansas.
Forward-Looking Statements:
Statements in this release that are "forward-looking statements" are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially because of factors such as: entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, changes in licensing programs, product price discounts, delays in product development and related product release schedules, sales channel disruption such as the bankruptcy of a major distributor, and reliance on sole source suppliers for key components that could result in delays in product delivery. Also, any of which may cause revenues and income to fall short of anticipated levels; technological shifts; the ability to have access to distribution channels that are controlled by third parties; the risk of unanticipated increased costs; the continued ability to protect the company's intellectual property rights; adverse effects on our business that might result if an unauthorized disclosure of a significant portion of our formula were to occur; the ability to obtain on acceptable terms the right to incorporate in the company's products and services; changes in product and service mix; maturing product life cycles; product sale terms and conditions; the risk that actual or perceived vulnerabilities in our products could adversely affect our revenues; implementation of operating cost structures that align with revenue growth; unavailability of insurance; uninsured losses; adverse results in litigation; unanticipated tax liabilities; the effects of terrorist activity and armed conflict such as disruptions in general economic activity and changes in our operations and security arrangements; the effects of a major earthquake, cyber-attack or other catastrophic event that results in the destruction or disruption of any of our critical business or information technology systems; the level of corporate information technology spending and changes in general economic conditions that affect demand; currency fluctuations; and financial market volatility or other changes affecting the value of our investments that may result in a reduction in carrying value and recognition of losses including impairment charges. Note to editors: If you are interested in viewing additional information on HEE Corp, please visit the HEE Corp web page at http://www.hee-corp.com/ on HEE Corp's information pages. Web links, telephone numbers and titles were correct at time of publication, but may since have changed. Shareholder and financial information is available at http://www.hee-corp.com/ .
Contact Information
Darci Brooks
HEE Corporation
http://www.hee-corp.com/
620-663-3333
HEE Corporation Inc.
Albert
DCGN biotecnology company Buy>>>>>>>>>>>>>>>>
PRAN
18, 2005 (M2 PRESSWIRE via COMTEX) --
Stock Watch: "In The News" (Pink Sheet: HCCF) HEE Corporation, (OTCBB: UGHO) UNIVERSAL GUARDIAN HOLDINGS INC(Pink Sheet: CSJJ) Coastal Holdings Inc., (News Update)
For More Information Go To W.W. OTCBB & Pinks @ http://www.willywizard.com (Pink Sheet: HCCF) HEE Corporation recently announced the "Shareholder's Advisory Board of HEE Corporation unanimously selected marketing firm media imPRessions from Chicago, IL (http://www.media-impressions.com) to assist in the promotion of their Diabetic treatment product HPB-84. After reviewing other PR firms, HEE Corporation and the Advisory Board feel that media imPRessions has the expertise, public relations knowledge and background to achieve HEE's short term and long term goals. The company helps clients distinguish themselves in today's intensely competitive world by delivering their message in creative, flexible and intelligent ways."
(OTCBB: UGHO) UNIVERSAL GUARDIAN HOLDINGS INC. recently "launched the Cobra StunLight(TM) Correctional Facility Program and will inaugurate its first training and Pilot Program with the Carroll County, New Hampshire Jail and House of Corrections."
(Pink Sheet: CSJJ) Coastal Holdings Inc. recently "announced its strategic decision to diversify its holdings by expanding into the high-growth, global Real Estate Development industry. The Company will diversify and focus on two industries: Technology (in particular Biotechnology with its equity interest in Vetdermal Systems Limited) and Real Estate Development."
All Press Releases Sources: http://finance.yahoo.com
CAUTIONARY STATEMENT: These news release excerpts may include forward-looking statements within the meaning of Section 21E of the United States Securities Exchange Act as amended, and/or the U.S. Private Securities Litigation Reform Act of 1995. All statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements that involve various risks and uncertainties. All forward-looking statements in this release are expressly qualified by this notice.
ABOUT WillyWizard.com
www.willywizard.com boosts it's newly designed web site with many informational investor links. WillyWizard.com has been in existence since 1999. The site is designed to be investor friendly for the novice investor to the experienced investor. You are invited to WillyWizard.com to have an experience you will not find anywhere.
To advertise at WillyWizard.com email willywizard@comcast.net
Many Programs to meet your company needs for successful advertising.
WillyWizard.com also hosts a live chat room at www.PalTalk.com listed under Premium Finance/Markets entitled WillyWizardsUnderground, password "rumble".
JOIN THE WILLYWIZARD EMAIL LIST @ (Cut and Paste Link in Your Browser)
http://tinyurl.com/5phvb
Albert
FNIX 52%
Moderator: albert
Assistants: None
Created: 5/17/2005 12:02:12 PM
http://edgar.brand.edgar-online.com/fetchFilingFrameset.aspx?FilingID=3613264&Type=HTML
dear belegger, friend This company goes a good future they a good invention has wanted you more know of this company mail then.
GOOD NEWS FROM THE COMPANY
I talked to Dari today and this is what I learned.
The "treatment" everyone is concerned about.
She said that she is not familar with the rules but that they are "very very carful about what we put out there" She said that they are working with FDA attornies out of New York.
She said the 'test' results would be out in two weeks,maybe sooner. The doctors were compileing the data now.
I asked about the chat with Becker. They talk every week.
Becker told her that everyone keeps bothering him about HCCF. She said that he does not want to talk about Hee but his new venture. She went on to say what we all should know that he cannot legally talk about it anyway.
They are very excited about the new PRfirm and that it came highly recomended.
She said that she is very excited about everything and that she now is thinking that the company is going to be bigger than she ever imagined.
And the best for last...
The marketing campain is to begin TOMORROW
there will be no press release because when they do one everyone just says "oh well" so they wont bother.
and if you dont believe any of this you can call her and ask
620 633 3333
Hccf Hee Corp
GOOD NEWS FROM THE COMPANY
I talked to Dari today and this is what I learned.
The "treatment" everyone is concerned about.
She said that she is not familar with the rules but that they are "very very carful about what we put out there" She said that they are working with FDA attornies out of New York.
She said the 'test' results would be out in two weeks,maybe sooner. The doctors were compileing the data now.
I asked about the chat with Becker. They talk every week.
Becker told her that everyone keeps bothering him about HCCF. She said that he does not want to talk about Hee but his new venture. She went on to say what we all should know that he cannot legally talk about it anyway.
They are very excited about the new PRfirm and that it came highly recomended.
She said that she is very excited about everything and that she now is thinking that the company is going to be bigger than she ever imagined.
And the best for last...
The marketing campain is to begin TOMORROW
there will be no press release because when they do one everyone just says "oh well" so they wont bother.
and if you dont believe any of this you can call her and ask
620 633 3333
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)
Diabetes Week
12 to 18 June 2005
In this article
What is Diabetes Week?
What is diabetes?
Causes
Symptoms
Managing diabetes
Where can I find out more?
What is Diabetes Week?
Diabetes Week is the annual campaign by Diabetes UK to increase the public's knowledge of diabetes, its symptoms and effects, and to raise funds for research into a cure.
What is diabetes?
Diabetes mellitus is a condition in which there's an excessive amount of glucose (sugar) in the blood. This occurs when the body can't use glucose properly because of a lack of insulin or when the insulin that is present doesn't work properly. Around 1.4 million people in the UK have been diagnosed with the condition, but it's estimated a further 1 million have the diabetes without knowing it.
There are two types of diabetes:
* Type 1 (insulin-dependent) diabetes occurs when the body is unable to produce any insulin.
* Type 2 (non-insulin dependent) diabetes occurs when the body produces insulin but it doesn' work properly or there isn't enough.
Causes
Glucose is produced when certain foods are digested. These foods include starchy products such as bread, rice, potatoes, chapatis and yams, and sugar and other sweet foods. Glucose is also produced by the liver.
Insulin is the hormone that helps this glucose enter the body's cells, where it's used as fuel. Without insulin or very little of it, this process can't take place, creating a build-up of sugar in the blood.
Symptoms
An excess of glucose in the blood can cause the following:
* increased thirst
* tiredness
* low energy levels
* unexplained weight loss
* blurred vision
* a frequent need to urinate, especially at night
There are complications that may arise from diabetes. One in four diabetics may go on to develop kidney disease, and eight per cent of diabetics are receiving some sort of treatment for this. People with diabetes are also two to four times more likely to develop cardiovascular disease.
Managing diabetes
The main aim of diabetes treatments is to achieve near normal blood glucose levels. Diabetes is managed by a combination of healthy diet, regular physical activity and sometimes tablets and insulin injections.
Where can I find out more?
Diabetes UK supports 200,000 members. The charity aims to help and care for people with diabetes and their families, to represent and campaign for their interests, and to fund research into the condition. Diabetes UK also advises the health profession, produces publications and operates a careline.
For more information, call 0845 120 2960 (Monday to Friday, 9am to 5pm) or go to www.diabetes.org.uk.
Media-Impressions looks like a very good company.
I would like to say that everybody should have a look at this site: http://www.media-impressions.com/case_studies.html
What they did with
CMP Healthcare Media
-Pharma Voice
-Medical Marketing Media
-Pharmaceutical Executive
-Pharmaceutical Marketing Congress
-MedAdNews
-Bloomberg
-Product Management Today
What they did for Lifegem
http://www.lifegem.com/secondary/news_home.asp
Dear friend, how more good news comes to how more itself is dumped has I 2.5 millions shares, I think still but what to buy on this nivo.
albert
Thank you for your e-mail concerning our product, HPB-84. Yes, we do have a manufacturer for our product and product is being manufactured at this time. Our manufacturer is in India and we expect to have product within 2-3 weeks from now. After this initial order, it is POSSIBLE that we will have a manufacturer within the United States that will be able to produce the exact same product for us. Also, we will be able to ship the product with 3-4 days from the time that people order it. The thing that makes me very happy about all of this is that this is a way that will make it possible for us to lower the price of the product substantially, as this manufacturer can sell it to us at a fraction of the cost that it is being sold to us now. It has been a goal of ours to make it possible to get this product into the hands of anybody who wants it. A much lower price makes this a much bigger possibility. This is only something that we are looking into at this time and we have signed no contracts with anybody as of yet. But if and when we do, we will put this out formally through a PR. In my opinion, this is an extremely positive thing!
This is a very exciting time for our company as we have many great things happening right now. Please be looking for future PR's to be released. I think that you will be very pleased with what you see.
Thank you again for your e-mail. I appreciate it when people have questions that they contact me rather than getting all of their information off of the internet. Let me know if you have further questions. I will be happy to answer them for you.
Kind regards,
Darci Brooks
Director of Investor Relations
HEE Corporation (HCCF.PK)
www.hee-corp.com
darci@hee-corp.com
(620)663-3333
Albert Brouwer
Friends, consider after rain come sun appearance Hup HEEEE
Albert
Dear friend, Busch are the Netherlands and yes hoor"gesproken and he they makes you no care this share hee goes the product well maketing doen.lijkt this you nicely or I did not ask still which rate aim, end of the year 030 dolar penny bad they I I that I will not speak him about this still in the wittehuis. nou to look Mr. Busch Albert
Hee Corp. (OTC: HCCF)
5/2/05 Close .008 Cents
Yes that is correct. This is not a profile, but a stock pick under a penny that had a 52 week high over $1.HCCF just launched a new site http://biz.yahoo.com/prnews/050422/cgf040.html?.v=4 HEE Corporation) has spent the past year testing and developing the promising remedy for Type II diabetes. The introduction of the web site marks the first time HPB-84 has been available for sale to the public.
The HEE Corporation
The HEE Corporation (OTCPK:HCCF) is a publicly traded company that was founded for the purpose of providing a corporate vehicle for marketing a new and extremely promising nutriceutical for Type II Diabetes. This nutriceutical was developed and tested in India . HEE Corp has the world-wide rights (exclusive of India ) and is currently bringing it to the market in the United States and Internationally. Based upon the highly successful results of the product in India , and the testimonials from those who have taken it here in the USA, HEE Corp is very excited about what we can do with the product world-wide.
Type II Diabetes has reached epidemic levels in The United States with 18.2 million confirmed cases and an estimated 5 million (nearly one-third of that total) not yet aware that they have Diabetes! Diabetes is the fifth leading cause of death by disease in the U.S.
Diabetes is now a modern-day epidemic, with some 171,000,000 people around the globe are estimated to have diabetes and the costs of treatment and productivity losses now run into the hundreds of billions of dollars worldwide. Type II Diabetes is the cause of many other ailments including heart disease, renal failure, blindness, skin problems and even loss of limbs. While there are treatments available for Diabetes they are often focused on treating the symptoms and not on eradicating the actual disease. Many of the side effects of prescription drugs for diabetes are uncomfortable for the patient and even dangerous.
While this is a relatively new product here in the USA , the promise of this revolutionary product cannot be ignored. While nutriceutical treatments have not received a huge following in the United States they have large followings in the rest of the world. HEE might not change medical history, but our product certainly does have a positive effect on those people who suffer from Type II Diabetes.
Please be aware that this stock trades in 20-30% ranges during the day. We have been adding to our position under .01.The nutriceutical arena will be hot this year.We own a large position bought in the open market and can sell at any time.
1 Year price target : .30 Cents
This Is a PR that HCCF came out with today. http://biz.yahoo.com/prnews/050503/cgtu041.html?.v=9
Read The last paragraph:
The Board's formation comes at a time when consumer recognition of HEE Corporation and HPB-84 is quickly growing. Over a four-day period last week, (Friday 4-22-05 afternoon through Tuesday 4-26-05), the company's corporate website received 174,000 hits in response to its announcement of HPB-84's availability.
This pick will go to the free list Wed night. We feel this could be our top % gainer of the year.
fair disclosure: We own a position in hccf.
Albert
Women naked, trade dead no trade today
HEE Corporation Names Advisory Board
Tuesday May 3, 7:00 am ET
Five Appointed to Help Define and Implement Business Strategies
HUTCHINSON, Kan., May 3 /PRNewswire-FirstCall/ -- HEE Corporation (OTC: HCCF - News) president Radley Brooks today named five individuals with wide- ranging business, nutritional and scientific backgrounds to the company's newly formed Board of Advisors. The Board will provide counsel to the company in areas of product development, marketing and overall corporate direction.
Named to the Board were Chad Ballinger, Keith Wiese, Arthur Peplow, Tim Palm, and Michael Moy. According to Brooks, "As we move from research, development and testing into product sales, the Board of Advisors will help guide us through the choppy seas growing companies face. The members of the Board have individual expertise in the fundamentals of business and marketing necessary to help HEE-Corporation grow and be successful."
Ballinger lives in Birmingham, Alabama and is a new business sales representative for Sam's Club, involved in marketing and advertising. His background is in corporate communications, including an internship with Smith Barney.
Wiese is one of HEE Corporation's primary share holders. He owns and operates Diversified Enterprises, Inc. in Plattsmouth, Nebraska.
Peplow of Richfield, Minnesota develops nutritional food products. He holds a Master's Degree in Food Science and Technology from the University of Florida.
Palm is an electrical engineer with expertise in product testing, quality assurance and materials handling. He holds a BSEE from the University of Florida and lives in Sarasota.
Moy lives in Courtland, Ohio, and is provider-certified for the Cleveland Clinic & University Hospital Health Care System. He specializes in ICD9 medical billing and coding and is a certified Medicaid and Medicare provider.
HEE Corporation recently announced the launch of its web-based product sales and information site, http://www.hpb84.net . The company is the exclusive international distributor of HPB-84, a nutraceutical remedy for Type II diabetes that the company has spent the past year testing and developing.
The Board of Advisors will provide guidance as HEE Corporation enters its marketing phase, and will help the company select a national/international marketing firm to aid in establishing the HPB-84 brand. HEE Corporation has identified and is negotiating with such firms.
The Board's formation comes at a time when consumer recognition of HEE Corporation and HPB-84 is quickly growing. Over a four-day period last week, (Friday 4-22-05 afternoon through Tuesday 4-26-05), the company's corporate website received 174,000 hits in response to its announcement of HPB-84's availability.
About HEE
HEE's headquarters is based in Hutchinson, Kansas.
Forward-Looking Statements
Dear friends of hee, well reported 174,000 applauding now still purchasers then come as good?
Albert
Dear friends, The sun seems still for hee, next week the first extradition nou still marketing then will seem for us the all sun this still more is none Danish but Dutch
Albert
Friends, I not now get frequently the behaviour of belegger getting off on a rate of 0,085 who have on this profit have faith in this venture the pill work the Internet site are well dedicate them time to grow further
Albert
Dear belegger/Gunnar/Txkat01 me can say to someone if have understood it where is that the first extradition on starts 29 April of the pill Hpb-84.Ik that the first yielded of May reported comes concerning marketing plan, is this where it is where that the pills come from India.
Albert
Gymnema Sylvestre or Gurmar (Sanskrit ) is another major ingredient in the Herbal formulation.Gymnema Sylvestre curtails the craving for sugar almost completely .Traditional physicians observed that chewing a few leaves of Gymnema sylvestre suppressed the taste of sugar. That is, sweet foods no longer tasted sweet, but rather became almost completely tasteless leading to vastly reduced craving for sugar
This is known as GURMAR or sugar killer in Sanskrit
n 1990 a series of published studies on Gymnema Sylvestre lifted this herb from interesting to revolutionary. To begin with, it was shown that the administration of GSE to diabetic animals not only resulted in improved glucose homeostasis, this improvement was accompanied by a regeneration of beta cells in the pancreas.) In the words of the authors, "Gymnema Sylvestre herbal therapy appears to bring about blood glucose homeostasis through increased serum insulin levels provided by repair/regeneration of the endocrine pancreas." Gymnema Sylvestre has shown the ability to lessen indicators of diabetes by directly repairing/regenerating the pancreas cells responsible for producing insulin. As abnormalities in beta cell number and/or function are directly related to both Type I (insulin dependent) and Type II diabetes mellitus
Dear friends, Indeth05 I on have looked up the plant which is indeed found in India in 1990.In the himalaya mount Albert
Gunnar/you me are possible telling how long the still durt for first sale see figures to outside bowls of hee. the Internet site there very well from these give much hope for the future.
Albert/Nederland
Gunnar/thank for your mail there are question also much in the Netherlands for this product I find, however, that much nonsense is spoken concerning this company on Raging Bull. thanks Albert